MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why PTN Stock dropped -3.33% Today — RQD Quant Desk Flash
$4.93 -3.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.89
Palatin Technologies Inc. (PTN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $8.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.89 (-0.79%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY PTN SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25.3 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$8.60-30% Next Q
46
Q2 (-2Q)Grade D$6.02-15.1% Next Q
43
Q3 (-1Q)Grade D$5.11-3.5% Next Q
41
CurrentGrade D-$4.93-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PTN Turnaround Squeeze
While PTN currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.15) and Max Pain ($5.18) forces dealer call-delta covering toward $32.55.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PTN Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PTN Stock dropped -3.33% Today — RQD Quant Desk Flash
Palatin Technologies Inc. (PTN) dropped -3.33% to $4.93, trading at 2% of its 52-week range ($4.51 – $31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($4.51 – $31) with RSI-14 at 25.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PTN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PTN)
- ✓Walkthrough of PTN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PTN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.61%🛡️ HOLDING TREND SUPPORT
2026-10-30O $4.93H $5.11L $4.90C $4.93VOL 16.0K
RES: $10.37SUP: $4.28SMA50: $9.15SMA200: $14.04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PTN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PTN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PTN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PTN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTN)
Health Care Rank #730 of 1016
⚔️ CMMB vs PTN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PTN vs. CMMB, INM, ENSC, MBRX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Palatin Technologies Inc. (PTN) ranks #730 by composite RQD confidence (38/100, grade D-) and #906 by equity capitalization ($8.8M). Within this direct 5-issuer industry benchmark cohort, PTN leads on earnings valuation at N/A trailing P/E, while PTN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PTN at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PTN
ACTIVE
Palatin Technologies Inc. | D- | 38/100 | — | — | -35.0% | -3.33% | $8.8M | Benchmark Subject |
| CMMB Chemomab Therapeutics Ltd. | D- | 38/100 | — | — | -35.0% | -0.91% | $8.8M | /cmmb-vs-ptn → |
| INM InMed Pharmaceuticals Inc. | D | 47/100 | — | 34.5% | -35.0% | +1.61% | $8.9M | /inm-vs-ptn → |
| ENSC Ensysce Biosciences Inc. | D- | 35/100 | — | — | -35.0% | -3.16% | $8.5M | /ensc-vs-ptn → |
| MBRX Moleculin Biotech Inc. | D- | 43/100 | — | — | -35.0% | -0.29% | $9.2M | /mbrx-vs-ptn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000911216In its most recent audited fiscal period (FY2025, filed 2025-06-30), Palatin Technologies Inc. (PTN) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.5M , and -100.0% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (+32.4% YoY). On the balance sheet, PTN closed FY2025 with $17.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$17.3M | -$21.3M | -$21.3M | $17.9M | — |
| FY2024 (FY) | 2024-06-30 | $4.5M | $29.7M | -$31.5M | -$31.5M | $4.3M | — |
| FY2023 (FY) | 2023-06-30 | $4.9M | $36.2M | -$29.3M | -$29.3M | — | — |
3. PTN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PTN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Palatin Technologies Inc. (NASDAQ: PTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.93 (-3.33% 1D, market cap $8.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PTN ranks #730 in composite RQD confidence.
How does PTN compare to CMMB and INM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMMB (Chemomab Therapeutics Ltd.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and INM (InMed Pharmaceuticals Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, PTN leads on earnings multiple (N/A) while PTN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PTN?
Per PTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000911216), Palatin Technologies Inc. generated $0 in revenue (-100.0% YoY), -$17.3M in net income, and -$21.3M in free cash flow against $17.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PTN trading relative to its 50-day, 200-day, and 52-week technical levels?
PTN last traded at $4.93 (-3.33% on volume of 12,223 shares), positioning the stock -46.12% below its 50-day simple moving average ($9.15) and -64.89% below its 200-day simple moving average ($14.04). Across its 52-week range of $4.51 to $31.00, PTN sits at the 1.6% percentile with a 14-day RSI of 25.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.31 to $5.55).
PTN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PTN stock moving today?
Why PTN Stock dropped -3.33% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.